Albany, NY -- (SBWIRE) -- 07/08/2019 -- Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast-2028
1. Renal cell carcinoma is more common in males than in females with a ratio of 3: 1
2. There was a higher expression of age up-regulated genes in older patients.
3. Approximately 73% of all patients with renal cell cancer survive for 5 years
DelveInsight launched a new report on Renal cell carcinoma Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Renal cell carcinoma market report covers a descriptive overview and comprehensive insight of the Renal cell carcinoma epidemiology and Renal cell carcinoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Renal cell carcinoma market report provides insights on the current and emerging therapies.
3. Renal cell carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Renal cell carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Renal cell carcinoma market.
Request for sample pages
"It is more frequent in patients with prior kidney disorders and accounts for approximately 30,000 new cases of kidney malignancies per year in the US"
Renal Cell Carcinoma treatment is dependent on several factors including the type, cell type and stage of cancer. It is most often treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, or a combination of these treatments.
Renal Cell Carcinoma market is expected to develop at a decent rate due to the increasing incidence rate. Development of novel agents have expanded Renal Cell Carcinoma market opportunities through larger number of patients under Renal Cell Carcinoma treatment and better treatment prospects compared to traditional therapies.
Renal Cell Carcinoma market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world and expected launch of Renal Cell Carcinoma emerging therapies during the forecast period of 2019-2028.
Drugs covered
1. Avelumab
2. CR-839
3. Keytruda/Inlyta
4. XL184
5. Atezolizumab
6. Bevacizumab
And many others
The key players in Renal Cell Carcinoma market are:
1. Merck KGaA
2. Calithera Biosciences
3. Merck Sharp & Dohme Corp.
4. Exelixis
5. Hoffmann-La Roche
And many others
Table of contents
1. Report Introduction
2. Renal Cell Carcinoma Market Overview at a Glance
3. Renal Cell Carcinoma Disease Background and Overview
4. Renal Cell Carcinoma Epidemiology and Patient Population
5. Renal Cell Carcinoma Epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Renal Cell Carcinoma Treatments & Medical Practices
7. Renal Cell Carcinoma Emerging Therapies
7.1. Key Cross Competition
7.2. CR-839: Calithera Biosciences
7.3. Keytruda/Inlyta: Merck Sharp & Dohme Corp.
8. Renal Cell Carcinoma Market Size
9. 7MM: Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. Italy Market Size
9.5. Spain Market Size
9.6. United Kingdom Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barriers
12. Report Methodology
13. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight